Form 4 for KRSA Korsana Biosciences, Inc.
Accepted 2023-12-04 00:00:00 ET · period of report 2023-11-30 · accession 0000950170-23-067740 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-04 | 2023-11-30 | KRSA | MCGUIRE TERRANCE | Dir | A - Grant | $0.00 | +5,000 | 5,552 | +906% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-30 | A | A | 5,000 | $0.00 | 5,552 | D | — | — | (F1) The Reporting Person was granted 5,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of these shares vest immediately and the remaining 2,500 of these shares vest over the next 6 months, provided that the Reporting Person remains as a director of Cylerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. |